Fortress Biotech (FBIO) 10-Q 10 May 16 2016 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2016	May. 09, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Entity Registrant Name	Fortress Biotech, Inc.
Entity Central Index Key	1,429,260
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Trading Symbol	FBIO
Entity Common Stock, Shares Outstanding		48,517,449

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Current assets
Cash and cash equivalents	$ 81,415	$ 98,182
Other receivables - related party	1,314	156
Prepaid expenses and other current assets	1,607	1,441
Total current assets	84,336	99,779
Property and equipment, net (Note 3)	2,598	309
Restricted cash	14,586	14,586
Long-term investments, at fair value (Note 4)	1,567	2,485
Intangible asset - licenses (Note 7)	1,450	1,250
Other assets	376	201
Total assets	104,913	118,610
Current liabilities
Accounts payable	2,348	1,868
Accrued expenses	8,259	8,570
Interest payable	27	27
Derivative warrant liability (Note 4)	203	114
Total current liabilities	10,837	10,579
Notes payable, long-term (net of debt discount of $466 and $835 at March 31, 2016 and December 31, 2015, respectively)	20,751	23,174
Other long-term liabilities	2,416	584
Total liabilities	$ 34,004	$ 34,337
Commitments and contingencies
Stockholders' equity
Common Stock, $.001 par value, 100,000,000 shares authorized, 48,517,449 and 47,147,032 shares issued and outstanding as of March 31, 2016 and December 31, 2015, respectively	$ 49	$ 47
Additional paid-in-capital	246,877	246,955
Accumulated deficit	(202,361)	(190,156)
Total stockholders' equity attributed to the Company	44,565	56,846
Non-controlling interests (Note 10)	26,344	27,427
Total stockholders' equity	70,909	84,273
Total liabilities and stockholders' equity	104,913	118,610
Series C Convertible Preferred Stock [Member]
Stockholders' equity
Convertible Preferred stock, $.001 par value, 129,767 Series C shares authorized, 0 shares issued and outstanding as of March 31, 2016 and December 31, 2015, respectively	$ 0	$ 0

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Debt Discount	$ 446	$ 835
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	100,000,000	100,000,000
Common Stock, shares issued	48,517,449	47,147,032
Common Stock, shares outstanding	48,517,449	47,147,032
Series C Convertible Preferred Stock [Member]
Preferred Stock, par value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	129,767	129,767
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenue	$ 383	$ 0
Revenue - from a related party	277	500
Total revenue	660	500
Operating expenses
Research and development	7,736	1,642
Research and development - licenses acquired	83	7,439
General and administrative	7,932	3,490
Total operating expenses	15,751	12,571
Loss from operations	(15,091)	(12,071)
Other income (expenses)
Interest income	75	82
Interest expense	(620)	(331)
Change in fair value of subsidiary's warrant liabilities	(89)	0
Change in fair value of investments	(918)	(215)
Total other income (expenses)	(1,552)	(464)
Net loss	(16,643)	(12,535)
Less: net loss attributable to non-controlling interests	4,438	479
Net loss attributable to common stockholders	$ (12,205)	$ (12,056)
Basic and diluted net loss per common share	$ (0.31)	$ (0.31)
Weighted average common shares outstanding—basic and diluted	39,658,188	38,574,702

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash Flows from Operating Activities:
Net Loss	$ (16,643)	$ (12,535)
Reconciliation of net loss to net cash used in operating activities:
Depreciation expense	4	6
Noncash interest expense	0	188
Amortization of debt discount	369	0
Stock-based compensation expense	2,866	1,470
Issuance of subsidiaries' common shares for license expenses	48	513
Change in fair value of investments	918	215
Change in fair value of subsidiary's warrant liabilities	89	0
Research and development-licenses acquired, expense	35	6,929
Unrealized gain on marketable securities	0	(2)
Realized gain on marketable securities	0	(1)
Increase (decrease) in cash and cash equivalents resulting from changes in operating assets and liabilities:
Other receivables - related party	(1,158)	0
Prepaid expenses and other current assets	(166)	22
Accounts payable and accrued expenses	169	1,853
Interest payable	0	(2)
Other	0	(61)
Other long-term liabilities	1,832	(500)
Net cash used in operating activities	(11,637)	(1,905)
Cash Flows from Investing Activities:
Purchase of research and development licenses	(35)	(6,929)
Purchase of property and equipment	(2,293)	0
Purchase of license	(200)	(1,250)
Payment to related parties - CB Pharma Acquisition Corp	(175)	(108)
Net cash used in investing activities	(2,703)	(8,287)
Cash Flows from Financing Activities:
Proceeds from exercise of stock options	0	216
Proceeds from subsidiary's offering - related party	570	0
Payment of costs related to subsidiary's offering	(205)	0
Payment of NSC note	(2,792)	0
Proceeds from NSC note	0	10,000
Payment of debt issue costs associated with NSC Note	0	(855)
Net cash (used in) provided by financing activities	(2,427)	9,361
Net decrease in cash and cash equivalents	(16,767)	(831)
Cash and cash equivalents at beginning of period	98,182	49,759
Cash and cash equivalents at end of period	81,415	48,928
Supplemental disclosure of cash flow information:
Cash paid for interest	77	80
Supplemental disclosure of non-cash financing and investing activities:
Issuance of restricted stock	$ 2	$ 1

Organization and Description of

Organization and Description of Business	3 Months Ended
	Mar. 31, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Description of Business	Fortress Biotech, Inc. (“Fortress” or “the Company”) is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress plans to continue to develop and commercialize products both within Fortress and its subsidiaries, also referred to herein as the “Fortress Companies”. In addition to its internal development programs, the Company plans to leverage its biopharmaceutical business expertise and drug development capabilities to help the Fortress Companies innovate, develop and commercialize products. Additionally, the Company will provide funding and management services to each of the Fortress Companies and, from time to time, the Company and the Fortress Companies will seek licensing, acquisitions, partnerships, joint ventures and/or public and private financings to accelerate and provide additional funding to support their research and development programs As of March 31, 2016, the Company has several consolidated Fortress Companies, which contain product licenses, including Avenue Therapeutics, Inc. (“Avenue”), Journey Medical Corporation (“JMC”), Coronado SO Co. (“Coronado SO”), Checkpoint Therapeutics, Inc. (“Checkpoint”), Mustang Bio, Inc. (“Mustang”), Helocyte, Inc. (“Helocyte”), Escala Therapeutics, Inc. (“Escala”) and other consolidated Fortress subsidiaries which have minimal activity, including Innmune Limited, CB Securities Corporation (holds investments classified as cash and cash equivalents in 2015 and 2016), and Cyprium Therapeutics, Inc

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period. The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the unaudited condensed consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding fiscal year. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Form 10-K, which was filed with the United States Securities and Exchange Commission (“SEC”) on March 15, 2016, from which the Company derived the balance sheet data at December 31, 2015. The Company’s unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries: Innmune Limited, Coronado SO, Cyprium Therapeutics, Inc., Escala, JMC, CB Securities Corporation, Avenue, Checkpoint, Mustang and Helocyte. All intercompany balances and transactions have been eliminated. The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period. The Company’s unaudited condensed consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, fair value measurements, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates. Reclassification Certain reclassifications have been made to prior year amounts to conform to the current year presentation in the condensed consolidated statements of cash flows. The Company follows accounting guidance on fair value measurements for financial assets and liabilities measured at fair value on a recurring basis. Under the accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance requires fair value measurements be classified and disclosed in one of the following three categories: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2: Observable inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. Certain of the Company’s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as accounts payable, accrued expenses and other current liabilities. The carrying value of the amount owed to Ovamed GmbH (“Ovamed”) upon the acquisition of certain manufacturing rights in December 2012 to under the amendment to our sublicense agreement with Ovamed has been recorded at its net present value, which approximates its fair value. The amounts due to Ovamed are included in current liabilities at March 31, 2016 and at December 31, 2015 on the condensed Consolidated Balance Sheets (see Note 9). The Company operates in one operating segment and, accordingly, no segment disclosures have been presented herein. All of the Company’s equipment, leasehold improvements and other fixed assets are physically located within the United States, and all agreements with the Company’s vendors are denominated in U.S. dollars. The Company considers highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at March 31, 2016 and at December 31, 2015 consisted of cash, money market funds and certificates of deposit in institutions in the United States. Balances at certain institutions have exceeded Federal Deposit Insurance Corporation insured limits and U.S. government agency securities. Office equipment is recorded at cost and depreciated using the straight-line method over the estimated useful life of each asset. Leasehold improvements are amortized over the shorter of the estimated useful lives or the term of the respective leases. The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value, determined based on discounted cash flows. The Company records cash held in trust or pledged to secure certain debt obligations as restricted cash. As of March 31, 2016, the Company has $ 14.6 14.0 0.6 The Company elects the fair value option for its long-term investments at fair value (see Note 4). The decision to elect the fair value option, which is irrevocable once elected, is determined on an instrument by instrument basis and applied to an entire instrument. The net gains or losses, if any, on an investment for which the fair value option has been elected are recognized as a change in fair value of investments on the condensed Consolidated Statements of Operations. The Company has various processes and controls in place to ensure that fair value is reasonably estimated. While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The Company records the costs of acquired product distribution license rights as intangible asset-licenses in the condensed Consolidated Balance Sheets. Upon commencement of product sales, license rights will be amortized over the expected life of the product into product expense in the condensed Consolidated Statements of Operations. As of March 31, 2016, product sales related to the Company’s intangible asset licenses had not yet commenced (see Note 7). Financing costs incurred in connection with the promissory note for $ 15.0 Reimbursement Arrangements and Collaborative Arrangements Checkpoint is reimbursed by TG Therapeutics, Inc. (“TGTX”), a related party, for its share of the cost of the license and product research and development costs under the collaboration agreement with them. The gross amount of these reimbursed costs are reported as revenue in the condensed Consolidated Statements of Operations, since the Company acts as a principal, bears credit risk and may perform part of the services required in the transactions. Consistent with Accounting Standards Codification (“ASC”) 605-45, Revenue Recognition - Principal Agent Considerations The Company recognizes revenue for the performance of services or the shipment of products when each of the following four criteria is met: (i) persuasive evidence of an arrangement exists; (ii) products are delivered or as services are rendered; (iii) the sales price is fixed or determinable; and (iv) collectability is reasonably assured. The Company follows ASC 605-25, Revenue Recognition - Multiple-Element Arrangements Collaborative Arrangements ASC 605-25 provides guidance relating to the separability of deliverables included in an arrangement into different units of accounting and the allocation of arrangement consideration to the units of accounting. The evaluation of multiple-element arrangements requires management to make judgments about (i) the identification of deliverables, (ii) whether such deliverables are separable from the other aspects of the contractual relationship, (iii) the estimated selling price of each deliverable, and (iv) the expected period of performance for each deliverable. To determine the units of accounting under a multiple-element arrangement, management evaluates certain separation criteria, including whether the deliverables have stand-alone value, based on the relevant facts and circumstances for each arrangement. Management then estimates the selling price for each unit of accounting and allocates the arrangement consideration to each unit utilizing the relative selling price method. The allocated consideration for each unit of accounting is recognized over the related obligation period in accordance with the applicable revenue recognition criteria. If there are deliverables in an arrangement that are not separable from other aspects of the contractual relationship, they are treated as a combined unit of accounting, with the allocated revenue for the combined unit recognized in a manner consistent with the revenue recognition applicable to the final deliverable in the combined unit. Payments received prior to satisfying the relevant revenue recognition criteria are recorded as deferred revenue in the condensed Consolidated Balance Sheets and recognized as revenue in the condensed Consolidated Statements of Operations when the related revenue recognition criteria are met. JMC’s co-promotion revenue for Dermasorb HC™ is based upon prescription volume over an established baseline Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on the Company’s behalf will be expensed as services are rendered or when the milestone is achieved. Research and development costs primarily consist of personnel related expenses, including salaries, benefits, travel, and other related expenses, stock-based compensation, payments made to third parties for license and milestone costs related to in-licensed products and technology, payments made to third party contract research organizations for preclinical and clinical studies, investigative sites for clinical trials, consultants, the cost of acquiring and manufacturing clinical trial materials, costs associated with regulatory filings, laboratory costs and other supplies. In accordance with ASC 730-10-25-1, Research and Development In accordance with ASC 815 – Derivatives and Hedging , the Company classified the fair value of the warrants (“Contingently Issuable Warrants”) granted in connection with the NSC Note transferred to Avenue effective February 2015 as a derivative liability. The Company valued these Contingently Issuable Warrants using an option pricing model, and used estimates for an expected dividend yield, a risk-free interest rate, and expected volatility together with management’s estimate of the probability of issuance of the Contingently Issuable Warrants (see Note 4 and Note 8). At each reporting period, as long as the Contingently Issuable Warrants were potentially issuable and there was a potential for an insufficient number of authorized shares available to settle the Contingently Issuable Warrants, these Contingently Issuable Warrants will be revalued and any difference from the previous valuation date would be recognized as a change in fair value of subsidiary’s warrant liabilities in the condensed Consolidated Statements of Operations The Company records accruals for contingencies and legal proceedings expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated. If a loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. The Company expenses stock-based compensation to employees over the requisite service period based on the estimated grant-date fair value of the awards and forfeiture rates. For stock-based compensation awards to non-employees, the Company remeasures the fair value of the non-employee awards at each reporting period prior to vesting and finally at the vesting date of the award. Changes in the estimated fair value of these non-employee awards are recognized as compensation expense in the period of change. The Company estimates the fair value of stock options grants using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. The Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax effects attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company establishes a valuation allowance if it is more likely than not that the deferred tax assets will not be recovered based on an evaluation of objective verifiable evidence. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the largest amount of the benefit that is greater than 50 Non-controlling interests in consolidated entities represent the component of equity in consolidated entities held by third parties. Any change in ownership of a subsidiary while the controlling financial interest is retained is accounted for as an equity transaction between the controlling and non-controlling interests (see Note 10). The Company’s comprehensive loss is equal to its net loss for all periods presented. In January 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Liabilities In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). ASU No. 2016-02 requires an entity to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. ASU No. 2016-02 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption is permitted. The Company currently in the process of evaluating the impact of adoption of ASU No. 2016-02 on the condensed consolidated financial statements and related disclosures. In March 2016, the FASB issued ASU No. 2016-08, “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations”. The purpose of ASU No. 2016-08 is to clarify the implementation of guidance on principal versus agent considerations. The amendments in ASU No. 2016-08 are effective for interim and annual reporting periods beginning after December 15, 2017. The Company is currently assessing the impact of ASU No. 2016-08 on the condensed consolidated financial statements and related disclosures. In March 2016, the FASB issued ASU No. 2016-09, “Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting”. The amendment is to simplify several aspects of the accounting for share-based payment transactions including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The amendments in ASU No. 2016-09 are effective for interim and annual reporting periods beginning after December 15, 2016. The Company is currently assessing the impact of ASU No. 2016-09 on the condensed consolidated financial statements and related disclosures.

Property and Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2016
Property Plant And Equipment [Abstract]
Property and Equipment	3. Property and Equipment March 31, December 31, ($ in thousands) Useful Life (Years) 2016 2015 Computer equipment 3 $ 391 $ 13 Furniture and fixtures 5 338 69 Leasehold improvements 5 20 21 Construction in progress (1) N/A 1,909 274 Total property and equipment 2,658 377 Less: Accumulated depreciation (60) (68) Property and equipment, net $ 2,598 $ 309 (1) For build-out of the Company's new office in New York, NY. Depreciation expense for the three months ended March 31, 2016 and 2015 was approximately $ 4,000 6,000 In January 2016, the Company wrote off approximately $ 12,000 depreciated leasehold improvements from 135 East 57 th , Street New York NY 10022 due to the termination of the sub-lease related to the office and Burlington due to the termination of the

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurement	4. Fair Value Measurements Certain of the Company’s financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as accounts payable, accrued expenses and other current liabilities. On March 17, 2014, the Company invested $ 250,000 35 13,409,962 83 16,091,954 250,000 As of March 31, 2016, the Company valued its investment in CB Pharma, a publicly traded company, utilizing the following assumptions: volatility of 25.6 9.61 9.82 25.6 1.21 11.50 0.98 0.94 10.25 0.97 1.00 0.10 0.10 0.9 1.3 42.5 0.5 0.3 Pursuant to the Amended NSC Note (see Note 8), if a Fortress Company has the proceeds of the NSC Note transferred to it, such Fortress Company will issue a note to NSC and NSC will also receive a warrant to purchase a number of shares of the Fortress Company’s stock equal to 25 10 Derivatives and Hedging 3.0 March 31, 2016 Risk-free interest rate 1.78 % Expected dividend yield - % Expected term in years 9.59 Expected volatility 83.00 % Probability of issuance of the warrant 45.00 % Fair Value of Derivative Warrant ($ in thousands) Liability Beginning balance at January 1, 2016 $ 114 Fair value adjustment of derivative warrant liability 89 Ending balance at March 31, 2016 $ 203 Fair Value Measurement as of March 31, 2016 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Long-term investments, at fair value $ - $ - $ 1,567 $ 1,567 Liabilities Derivative warrant liability $ - $ - $ 203 $ 203 Fair Value Measurement as of December 31, 2015 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Long-term investments, at fair value $ - $ - $ 2,485 $ 2,485 Liabilities Derivative warrant liability $ - $ - $ 114 $ 114 Fair Value of Investment Long-term ($ in thousands) Other CB Pharma Total Balance at December 31, 2015 $ 250 $ 2,235 $ 2,485 Change in fair value of investments - (918) (918) Balance at March 31, 2016 $ 250 $ 1,317 $ 1,567 Fair Value of Investment Long-term ($ in thousands) Other CB Pharma Total Balance at December 31, 2014 $ 250 $ 3,910 $ 4,160 Change in fair value of investments - (215) (215) Balance at March 31, 2015 $ 250 $ 3,695 $ 3,945 For the three months ended March 31, 2016 and 2015, no transfers occurred between Level 1, Level 2 and Level 3 instruments.

Licenses Acquired

Licenses Acquired	3 Months Ended
	Mar. 31, 2016
Licenses Acquired [Abstract]
Licenses Acquired	5. Licenses Acquired In accordance with ASC 730-10-25-1, Research and Development 83,000 7.4 For the Three Months Ended March 31, ($ in thousands) 2016 2015 Fortress Companies: Avenue $ - $ 2,000 Checkpoint - 2,000 Coronado SO - 1,179 Helocyte 83 - Mustang - 2,260 Total $ 83 $ 7,439 Avenue Therapeutics, Inc. License Agreement with Revogenex Ireland Ltd In February 2015, the Company purchased an exclusive license to IV Tramadol for the U.S. market from Revogenex, a privately held company in Dublin, Ireland. Fortress made an upfront payment of $ 2.0 1.0 The Company transferred the Revogenex license and all other rights and obligations of Fortress under the License Agreement to Avenue pursuant to the Assignment and Assumption Agreement effective as of February 17, 2015. Per the terms of the agreement, Avenue assumed $ 3.0 During the three months ended March 31, 2016, Avenue completed a pharmacokinetics or PK study for IV Tramadol. Checkpoint Therapeutics, Inc. License Agreement with Dana-Farber Cancer Institute In March 2015, Checkpoint entered into a license agreement with Dana-Farber to develop a portfolio of fully human immuno-oncology targeted antibodies. Under the terms of the agreement, Checkpoint paid Dana-Farber an up-front licensing fee of $ 1.0 500,000 32,500 0.065 136,803 0.6 4.39 Collaboration Agreements with TG Therapeutics, Inc. In connection with its license agreement with Dana-Farber, Checkpoint entered into a collaboration agreement with TG Therapeutics, Inc. (“TGTX”), a related party, to develop and commercialize the Anti-PD-L1 and Anti-GITR antibody research programs in the field of hematological malignancies. Under the terms of the collaboration agreement, Checkpoint retains the right to develop and commercialize these antibodies in the field of solid tumors. Both programs are currently in pre-clinical development. TGTX paid Checkpoint $ 0.5 17,000 0.5 In connection with its license with NeuPharma, Checkpoint entered into an option with TGTX for $ 25,000 NeuPharma, Inc. Effective March 17, 2015, the Company assigned all of its rights under its agreement with NeuPharma to develop and commercialize novel irreversible, third generation EGFR inhibitors on a worldwide basis other than certain Asian countries, to Checkpoint in exchange for debt. Under the terms of the agreement, Fortress paid NeuPharma an upfront licensing fee of $ 1.0 On September 15, 2015, Checkpoint entered into a sponsored research agreement with NeuPharma to identify additional inhibitors with differing profiles from the licensed products. Under the terms of the agreement, Checkpoint will pay NeuPharma for specific sponsored research projects. Effective January 11, 2016, TGTX agreed to assume all costs associated with this agreement and reimbursed Checkpoint for all amounts paid previously by Checkpoint and the Company recognized $ 0.3 Teva Pharmaceutical Industries Ltd. (through its subsidiary, Cephalon, Inc.) In December 2015, Checkpoint licensed, for $ 0.5 Coronado SO Company License Agreement In February 2015, Coronado SO entered into an exclusive license agreement with a third party for a topical product used in the treatment of hand-foot syndrome, a common painful side effect of chemotherapeutics. Coronado SO paid $ 0.9 150,000 0.5 The Company valued the stock grant to the third party utilizing a discounted cash flow model to determine the weighted market value of invested capital, discounted by a lack of marketability of 44.8 30 1.19 Helocyte, Inc. License Agreement with the City of Hope In March 2016, Helocyte entered into amended and restated license agreements for each of its PepVax and Triplex immunotherapies programs with its licensor City of Hope National Medical Center (“COH”). The amended and restated licenses expand the intellectual property and other rights granted to Helocyte by COH in the original license agreement. The financial terms of the original license have not been modified, and if Helocyte successfully develops and commercializes PepVax and Triplex, COH will receive milestones, royalties and other payments. Helocyte entered into the original license agreement with COH on April 2, 2015, to secure: (i) an exclusive worldwide license for two immunotherapies for CMV control in the post-transplant setting (known as Triplex and PepVax); and (ii) an option for an exclusive worldwide license to an immunotherapy for the prevention of congenital CMV (known as Pentamer). In consideration for the license and option, Helocyte made an upfront payment of $ 150,000 50,000 As further consideration for the license, in March 2016, Helocyte granted to COH 500,000 44.5 30 0.097 48,500 University of Texas License Option In February 2016, the Company entered into an option agreement for $ 35,000 Escala Therapeutics, Inc. On July 16, 2015, Escala acquired from New Zealand Pharmaceuticals Limited (“NZP”) a license from the National Institute of Health (“NIH”) and cooperative research and development agreements for the development of oral ManNAc, a key compound in the sialic biosynthetic pathway, for the treatment of hyposialylation disorders, including GNE myopathy and various forms of nephropathy. As part of this agreement, Escala provided NZP and NIH an upfront payment of approximately $ 1.3 0.7 0.6 Mustang Bio, Inc. License Agreement with the City of Hope In March 2015, Mustang entered into a license agreement with the COH to acquire CAR-T. Pursuant to the agreement, in April 2015, Mustang paid COH an upfront fee of $ 2.0 1,000,000 The Company valued the stock grant to COH utilizing a discounted cash flow model to determine the weighted market value of invested capital, discounted by a lack of marketability of 44.8 30 0.147 0.1

Milestones and Sponsored Resear

Milestones and Sponsored Research Agreements	3 Months Ended
	Mar. 31, 2016
Research and Development [Abstract]
Research, Development, and Computer Software Disclosure	6. Milestones and Sponsored Research Agreements Helocyte In March 2016, Helocyte entered into an Investigator-Initiated Clinical Research Support Agreement with the City of Hope National Medical Center, to support a Phase 2 clinical study of its PepVax immunotherapy for CMV control in allogeneic stem cell transplant recipients. The Phase 2 study is additionally supported by grants from the National Cancer Institute. Under the terms of the agreement, Helocyte made an upfront payment to COH of $ 1.0 2.0 In February 2016, Helocyte entered into an Investigator-Initiated Clinical Research Support Agreement with the City of Hope National Medical Center, to support a Phase 2 clinical study of its Triplex immunotherapy for CMV control in allogeneic stem cell transplant recipients. The Phase 2 study is additionally supported by grants from the National Cancer Institute. Under the terms of the agreement, Helocyte made an upfront payment to COH of $ 1.0 3.4 For the three month ended March 31, 2016, Helocyte incurred expense of $2.0 million, related to the sponsored research agreements, recorded as research and development expense in the Company’s Condensed Consolidated Statement of Operations. Mustang In March 2015, in connection with Mustang’s license with COH for the development of CAR-T, Mustang entered into a Sponsored Research Agreement in which Mustang will fund continued research in the amount of $ 2.0 0.5 CNDO-109 The Company has a license agreement with the University College London Business PLC (“UCLB”) under which the Company received an exclusive, worldwide license to develop and commercialize CNDO-109 to active NK cells for the treatment of cancer-related and other conditions. In consideration for the license, the Company made upfront payments totaling $ 0.1 22 0.4 3 5

Intangible Asset Licenses

Intangible Asset Licenses	3 Months Ended
	Mar. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Asset License	7. Intangible Asset Licenses Journey Medical Corporation In January 2016, JMC entered into a licensing agreement with a third party to distribute a prescription wound cream. JMC intends to commercialize this product in mid-2016. There was no upfront payment for this license. In January 2016, JMC entered into a licensing agreement with a third party to distribute an emollient for the treatment of various types of dermatitis. JMC paid an upfront fee of $ 0.2 In March 2015, JMC entered into a license and supply agreement to acquire the rights to distribute a dermatological product for the treatment of acne. JMC made an upfront payment of $ 1.3 0.7 The Company recorded the upfront payments as an intangible asset on the Condensed Consolidated Balance Sheets and will amortize them over the deemed life of the products or agreements (whichever is shorter) upon the commencement of sales, which the Company expects in mid-2016.

Debt and Interest

Debt and Interest	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Debt and Interest	8. Debt and Interest Debt Interest ($ in thousands) March 31, 2016 December 31, Rate Maturity IDB Note $ 14,009 $ 14,009 2.25 % Feb - 2017 NSC Note 7,208 10,000 8.00 % Mar - 2018 Total notes payable, long-term 21,217 24,009 Less: Discount on notes payable 466 835 Total notes payable, long-term, net $ 20,751 $ 23,174 IDB Note On February 13, 2014, the Company executed a promissory note in favor of IDB in the amount of $ 15.0 14 100,000 100,000 2.25 The obligations of the Company under the IDB Note are collateralized by a security interest in, a general lien upon, and a right of set-off against the Company’s money market account of $ 15.0 The Company will default on the IDB Note if, among other things, it fails to pay outstanding principal or interest when due. Following the occurrence of an event of default under the IDB Note, the Bank may: (i) declare the entire outstanding principal balance of the IDB Note, together with all accrued interest and other sums due under the IDB Note, to be immediately due and payable; (ii) exercise its right of setoff against any money, funds, credits or other property of any nature in possession of, under control or custody of, or on deposit with IDB; (iii) terminate the commitments of IDB; and (iv) liquidate the money market account to reduce the Company’s obligations to IDB. Effective March 31, 2015, the Company extended the maturity date of the IDB Note to February 27, 2017. At March 31, 2016, the Company had approximately $ 14.0 NSC Note In March 2015, the Company closed a private placement of a promissory note for $ 10 8 0.9 12.4 The NSC Note was amended and restated on July 29, 2015 to provide that any time a Fortress subsidiary receives from the Company any proceeds from the NSC Note, the Company may, in its sole discretion, cause the Fortress Company to issue to NSC Biotech Venture Fund I LLC a new promissory note (the “Amended NSC Note”) on identical terms as the NSC Note, giving effect to the passage of time with respect to maturity. The Amended NSC Note will equal the dollar amount of the Fortress Company’s share of the NSC Note and reduce the Company’s obligations under the NSC Note by such amount. The Company will guarantee the Amended NSC Note until the Fortress Company either completes an initial public offering of its securities or raises sufficient equity capital so that it has cash equal to five times the Amended NSC Note. As of March 31, 2016, the Company transferred $ 2.8 3.0 In connection with the transfer of NSC Note proceeds to a Fortress Company, NSC will receive a warrant to purchase the Fortress Company’s stock equal to 25 10 As of March 31, 2016, Avenue recorded approximately $ 267,500 113,500 In February 2016, Checkpoint repaid its NSC Debt of $ 2.8 324,000 174,000 The Company’s Chairman, President and Chief Executive Officer and the Company’s Executive Vice President, Strategic Development, are Co-Portfolio Managers and Partners of Opus Point Partners Management, LLC (“OPPM”), which owns approximately 4.2 IDB Letters of Credit The Company has several letters of credit (“LOC”) with IDB securing rent deposits for lease facilities totaling approximately $ 1.7 2 For the Three Months Ended March 31, ($ in thousands) 2016 2015 IDB Note Interest $ 80 $ 69 Amortization of fees 1 1 Total IDB Note 81 70 NSC Debt Interest 167 72 Amortization of fees 368 20 Total NSC Debt 535 92 Ovamed Interest - 167 Total Ovamed - 167 LOC Fees Interest 4 2 Total LOC 4 2 Total Interest Expense $ 620 $ 331

Accrued Expenses and Other Long

Accrued Expenses and Other Long-Term Liabilities	3 Months Ended
	Mar. 31, 2016
Payables and Accruals [Abstract]
Accrued Expenses and Other Long-Term Liabilities	9. Accrued Expenses and Other Long-Term Liabilities March 31, December 31, ($ in thousands) 2016 2015 Accrued expenses: Professional fees $ 749 $ 382 Salaries, bonuses and related benefits 762 2,492 Ovamed manufacturing rights - short term component 1,500 1,500 Research and development 746 810 Dr. Falk Pharma milestone 2,828 2,717 COH upfront fee for sponsored research for PepVax (see Note 6) 1,007 - Accrued lease costs for abandoned properties 146 146 Other 521 523 Total accrued expenses $ 8,259 $ 8,570 Other long-term liabilities: Long-term accrued lease costs for abandoned properties 17 91 Deferred rent 2,399 493 Total other long-term liabilities $ 2,416 $ 584

Non-Controlling Interests

Non-Controlling Interests	3 Months Ended
	Mar. 31, 2016
Noncontrolling Interest [Abstract]
Non-Controlling Interests	10. Non-Controlling Interests As of March 31, 2016 ($ in thousands) Avenue Coronado SO Mustang Checkpoint JMC Helocyte Total NCI equity share $ (560) $ (217) $ (359) $ 32,623 $ (299) $ (406) $ 30,782 Net loss attributed to non-controlling interests (108) (5) (70) (4,037) (121) (97) (4,438) Non-controlling interests in consolidated entities $ (668) $ (222) $ (429) $ 28,586 $ (420) $ (503) $ 26,344 As of December 31, 2015 ($ in thousands) Avenue Coronado SO Mustang Checkpoint JMC Total NCI equity share $ 6 $ 23 $ 14 $ 32,760 $ 79 $ 32,882 Net loss attributed to non-controlling interests (567) (240) (373) (3,855) (420) (5,455) Non-controlling interests in consolidated entities $ (561) $ (217) $ (359) $ 28,905 $ (341) $ 27,427 For the three months ended March 31, 2016 ($ in thousands) Avenue Coronado SO Mustang Checkpoint JMC Helocyte Total Non-controlling interests in loss of consolidated entities $ (108) $ (5) $ (70) $ (4,037) $ (121) $ (97) $ (4,438) Non-controlling ownership 11.5 % 13.0 % 10.0 % 62.7 % (1) 8.1 % 8.3 % (1) Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights. For the three months ended March 31, 2015 ($ in thousands) Coronado SO Mustang Checkpoint Total Non-controlling interests in loss of consolidated entities $ (160) $ (226) $ (93) $ (479) Non-controlling ownership 13.0 % 10.0 % 15.0 %

Net Loss per Common Share

Net Loss per Common Share	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Net Loss Per Common Share	11. Net Loss per Common Share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common stock and common stock equivalents outstanding for the period. Included in common stock issued and outstanding as of March 31, 2016 are 8,059,258 The Company’s potential dilutive securities which consist of unvested restricted stock, options, and warrants have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average common stock outstanding used to calculate both basic and diluted net loss per share is the same. For the Three Months Ended March 31, 2016 2015 Warrants to purchase Common Stock 544,835 685,061 Options to purchase Common Stock 1,779,365 2,064,365 Unvested Restricted Stock 7,922,021 7,704,269 Unvested Restricted Stock Units 885,083 36,000 Total 11,131,304 10,489,695

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2016
Stockholders' Equity Note [Abstract]
Stockholders’ Equity	12. Stockholders’ Equity Stock-based Compensation As of March 31, 2016, the Company had four equity compensation plans: the Fortress Biotech, Inc. 2007 Stock Incentive Plan, the Fortress Biotech, Inc. 2013 Stock Incentive Plan, the Fortress Biotech, Inc. 2012 Employee Stock Purchase Plan and the Fortress Biotech. Inc. Long Term Incentive Plan (“LTIP”). For the Three Months Ended March 31, ($ in thousands) 2016 2015 Employee awards $ 1,584 $ 1,463 Non-employee awards 3 7 Fortress Companies (1) 1,279 - Total stock-based compensation expense $ 2,866 $ 1,470 (1) Consists of approximately $ 9,000 1.1 181,000 For the three months ended March 31, 2016 and 2015, approximately $ 1.3 0.3 1.6 1.2 In February 2016, the Company modified the vesting schedule on 1.9 3.9 0.4 Weighted average Total weighted remaining Weighted average average intrinsic contractual life Number of shares exercise price value (years) Options vested and expected to vest at December 31, 2015 1,779,365 $ 4.37 $ 666,396 6.32 Options granted - - - Options vested and expected to vest at March 31, 2016 1,779,365 $ 4.37 $ 853,984 6.07 Options vested and exercisable 1,082,168 $ 3.75 $ 805,651 5.62 As of March 31, 2016, the Company had unrecognized stock-based compensation expense related to unvested option of $ 62,000 0.1 Weighted average Number of shares grant price Unvested balance at December 31, 2015 8,757,935 $ 2.47 Restricted stock granted 1,240,868 2.77 Restricted stock vested (989,782) 2.73 Restricted stock units granted 165,000 3.22 Restricted stock units cancelled (25,000) 3.71 Restricted stock units vested (341,917) 3.55 Unvested balance at March 31, 2016 8,807,104 $ 2.45 As of March 31, 2016, the Company had unrecognized stock-based compensation expense related to restricted stock and restricted stock unit awards of approximately $ 4.1 0.7 2.7 1.3 Employee Stock Purchase Plan Eligible employees can purchase the Company’s Common Stock at the end of a predetermined offering period at 85 As of March 31, 2016, 91,192 108,808 9,000 Warrants Total weighted Weighted average Weighted average average intrinsic remaining contractual Number of shares exercise price value life (years) Outstanding as of December 31, 2015 569,835 $ 6.31 $ 120,700 1.84 Exercised (*) (25,000) 1.37 43,250 Outstanding as of March 31, 2016 544,835 $ 6.53 $ 103,800 1.67 Exercisable as of March 31, 2016 544,835 $ 6.53 $ 103,800 1.67 (*) - cashless All stock-based expense in connection with these warrants has been recognized prior to January 1, 2016. Long-Term Incentive Program (“LTIP”) On July 15, 2015, the stockholders approved the LTIP for the Company’s Chairman, President and Chief Executive Officer, Dr. Rosenwald, and Executive Vice Chairman, Strategic Development, Mr. Weiss. The LTIP consists of a program to grant equity interests in the Company and in the Company’s subsidiaries, and a performance-based bonus program that is designed to result in performance-based compensation that is deductible without limit under Section 162(m) of the Internal Revenue Code of 1986, as amended. 500,000 44.8 30 2.2 On January 1, 2016, the Compensation Committee granted 510,434 1 100,000,000, market condition , Compensation – Stock Compensation 2.37 2.4 Fortress Companies Checkpoint Therapeutics, Inc. Checkpoint has a long-term incentive plan. In March 2015, Checkpoint issued a restricted stock grant to Dr. Marasco for services in connection with its Scientific Advisory Board. Dr. Marasco was issued a grant for 1.5 25 48 44.8 30 0.065 4.39 83 1.5 0.8 4.39 On January 8, 2016, Checkpoint granted one of its Board members 50,000 50,000 4.39 1.5 83 0.3 Avenue Therapeutics, Inc. Avenue has a long term incentive program. During 2015, Avenue granted 1.0 44.8 30 0.146 50 12.5 50 5,000 5,000 Journey Medical Corporation In January 2016, JMC granted 305,000 44.5 30 0.65 0 For the three months ended March 31, 2016 Risk-free interest rate 1.46% - 1.82 % Expected dividend yield - Expected term in years 5.23-6.95 Expected volatility 96.89% - 102.05 % During the three months ended March 31, 2016, stock-based compensation associated with the amortization of stock option expense was approximately $ 0.1 35,000 Helocyte, Inc. On March 28, 2016, Helocyte granted 150,000 0.097 83 1.5 62 On March 30, 2016, Helocyte granted 1.0 0.097 500 Capital Raise On February 23, 2016, Checkpoint closed on gross proceeds of $ 0.6 10,000 3,500 7.00 45,000 126,640 44,324

Related Party Note

Related Party Note	3 Months Ended
	Mar. 31, 2016
Related Party Transactions [Abstract]
Related Party Note	13. Related Party Note Related Party Service Agreement Other Related Parties The Company’s Chairman, President and Chief Executive Officer, individually and through certain trusts over which he has voting and dispositive control, beneficially owned approximately 12.9 12.2 15.4 14.8 Services Agreement with Opus Point Management Partners, LLC On April 3, 2014, the Company entered into a Shared Services Agreement with OPPM in which the parties agreed to share a rented facility as well as costs for certain services, which they individually require for the operation of their respective entities. The Company’s Chairman, President and Chief Executive Officer and the Company’s Executive Vice Chairman, Strategic Development are both Co-Portfolio Managers and Partners of OPPM. The Company incurred expense of approximately $ 63,000 40,000 Shared Services Agreement with TGTX In July 2015, TGTX and the Company entered into an arrangement to share the cost of certain research and development employees. The Company’s Executive Vice Chairman, Strategic Development, is Executive Chairman and Interim Chief Executive Officer of TGTX. Under the terms of the Agreement, TGTX will reimburse the Company for the salary and benefit costs associated with these employees based upon actual hours worked on TGTX related projects. For the three months ended March 31, 2016, the Company invoiced TGTX $ 0.1 Desk Share Agreement with TGTX and OPPM In September 2014, the Company entered into Desk Space Agreement, with OPPM and TGTX, to occupy 20 40 0.5 1.1 The initial Desk Share Agreement is for 5 5.1 199,000 39,800 79,800 2.3 1.0 0.2 Checkpoint Collaboration Agreements with TGTX In connection with the license agreement with Dana-Farber, Checkpoint entered into a collaboration agreement with TGTX to develop and commercialize the Anti-PD-L1 and Anti-GITR antibody research programs in the field of hematological malignancies. In connection with this agreement, TGTX paid Checkpoint $ 17,000 0.5 In addition, effective January 11, 2016, TGTX agreed to assume all costs associated with Checkpoint’s Sponsored Research Agreement. In connection with this agreement, Checkpoint recognized revenue of $ 0.3 Founders Agreement and Management Services Agreement with Checkpoint Effective March 17, 2015, the Company entered into a Founders Agreement with Checkpoint pursuant to which the Company assigned to Checkpoint all of its rights and interest (i) under the Company’s license agreement for the EGFR inhibitors and (ii) to a license agreement currently under negotiation, as set forth in the Founders Agreement. As consideration for the Founders Agreement, Checkpoint assumed $ 2.8 Effective as of March 17, 2015, the Company entered into a Management Services Agreement (the “MSA”) with Checkpoint and each of Checkpoint’s current directors and officers who are directors or officers of the Company to provide services to Checkpoint pursuant to the terms of the MSA. Pursuant to the terms of the MSA, for a period of five (5) years, the Company will render advisory and consulting services to Checkpoint. Services provided under the MSA may include, without limitation, (i) advice and assistance concerning any and all aspects of Checkpoint’s operations, clinical trials, financial planning and strategic transactions and financings and (ii) conducting relations on behalf of Checkpoint with accountants, attorneys, financial advisors and other professionals. Checkpoint is obligated to utilize clinical research services, medical education, communication and marketing services and investor relations/public relation services of companies or individuals designated by Fortress, provided those services are offered at market prices. However, Checkpoint is not obligated to take or act upon any advice rendered from Fortress and Fortress shall not be liable for any of Checkpoint’s actions or inactions based upon their advice. Fortress and its affiliates, including all members of Checkpoint’s Board of Directors, have been contractually exempt from fiduciary duties to Checkpoint relating to corporate opportunities. In consideration for the Services, the Company will pay Fortress an annual consulting fee of $ 0.5 1.0 100 Founders Agreement and Management Services Agreement with Avenue Effective as of February 17, 2015, the Company entered into a Founders Agreement with Avenue pursuant to which the Company assigned to Avenue all of its rights and interest under the Company’s license agreement with Revogenex for IV Tramadol. As consideration for the Founders Agreement, Avenue assumed $ 3.0 Effective as of February 17, 2015, the Company entered into a Management Services Agreement (the “MSA”) with Avenue and each of Avenue’s current directors and officers who are directors or officers of the Company to provide services to Avenue pursuant to the terms of the MSA. Pursuant to the terms of the MSA, for a period of five (5) years, the Company will render advisory and consulting services to Avenue. Services provided under the MSA may include, without limitation, (i) advice and assistance concerning any and all aspects of Avenue’s operations, clinical trials, financial planning and strategic transactions and financings and (ii) conducting relations on behalf of Avenue with accountants, attorneys, financial advisors and other professionals (collectively, the “Services”). Avenue is obligated to utilize clinical research services, medical education, communication and marketing services and investor relations/public relation services of companies or individuals designated by Fortress, provided those services are offered at market prices. However, Avenue is not obligated to take or act upon any advice rendered from Fortress and Fortress shall not be liable for any of Avenue’s actions or inactions based upon their advice. Fortress and its affiliates, including all members of Avenue’s Board of Directors, have been contractually exempt from fiduciary duties to Avenue relating to corporate opportunities. In consideration for the Services, the Company will pay Fortress an annual consulting fee of $ 0.5 1.0 100 Founders Agreement and Management Services Agreement with Helocyte Effective March 20, 2015, the Company entered into a Founders Agreement with Helocyte pursuant to which the Company agreed to provide the initial funding required by the COH License Agreement for PepVax and Triplex, as well as other operating capital needed to meet the Helocyte’s initial requirements. As consideration for the Founders Agreement, upon Helocyte commencing a third party financing, Helocyte will assume the Company’s accumulated debt, attributable to Helocyte’s expenses and costs associated with its formation, license acquisition and expenses, under the NSC Biotech Venture Fund I, LLC Promissory Note (“NSC Note”), or other similar debt. As additional consideration for the transfer of rights under the Founders Agreement, Helocyte will also: (i) issue annually to the Company, on the anniversary date of the Founders Agreement, shares of common stock equal to two and one half percent (2.5%) of the fully-diluted outstanding equity of Helocyte at the time of issuance; (ii) pay an equity fee in shares of Helocyte common stock, payable within five (5) business days of the closing of any equity or debt financing for Helocyte or any of its respective subsidiaries that occurs after the effective date of the Founders Agreement and ending on the date when Fortress no longer has majority voting control in Helocyte’s voting equity, equal to two and one half percent (2.5%) of the gross amount of any such equity or debt financing; and (iii) pay a cash fee equal to four and one half percent (4.5%) of our annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a change in control (as it is defined in the Founders Agreement), the Company will pay a one-time change in control fee equal to five (5x) times the product of (i) monthly net sales for the twelve (12) months immediately preceding the change in control and (ii) four and one-half percent (4.5%). Effective March 20, 2015, the Company entered into a Management Services Agreement (the “MSA”) with Helocyte and each of Helocyte’s current directors and officers who are directors or officers of the Company to provide services to Helocyte pursuant to the terms of the MSA. Pursuant to the terms of the MSA, for a period of five (5) years, the Company will render advisory and consulting services to Helocyte. Services provided under the MSA may include, without limitation, (i) advice and assistance concerning any and all aspects of Helocyte’s operations, clinical trials, financial planning and strategic transactions and financings and (ii) conducting relations on behalf of Helocyte with accountants, attorneys, financial advisors and other professionals (collectively, the “Services”). Helocyte is obligated to utilize clinical research services, medical education, communication and marketing services and investor relations/public relation services of companies or individuals designated by Fortress, provided those services are offered at market prices. However, Helocyte is not obligated to take or act upon any advice rendered from Fortress and Fortress shall not be liable for any of Helocyte’s actions or inactions based upon their advice. Fortress and its affiliates, including all members of Helocyte’s Board of Directors, have been contractually exempt from fiduciary duties to Helocyte relating to corporate opportunities. In consideration for the Services, the Company will pay Fortress an annual consulting fee of $ 0.5 1.0 100 CB Pharma Acquisition Corp. The Company has committed to provide working capital of up to $ 0.5 0.3 0.2 Chord Advisors, LLC In May 2015, we entered into a full service consulting agreement with Chord Advisors, LLC (“Chord”) to provide advisory accounting services to us. Under the terms of the agreement, we pay Chord $ 10,000 5,000 7,500

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events Merger Agreement with National Holdings Corporation On April 27, 2016, the Company, its wholly owned subsidiary, FBIO Acquisition, Inc. (“Acquisition Sub”), a Delaware corporation and National Holdings Corporation (“NHLD”), a Delaware corporation, entered into an Agreement and Plan of Merger (“Merger Agreement”) for the acquisition of NHLD by Acquisition Sub. Fortress entered into the transaction in part because of NHLD’s ability to finance emerging biotech transactions. Pursuant to the Merger Agreement and upon the terms and subject to the conditions therein, Fortress has agreed to cause Acquisition Sub to commence a tender offer (the “Offer”) as promptly as practicable and in no event later that 30 days after the Financial Industry Regulatory Authority (“FINRA”) declares the application required under NASD Rule 1017 regarding the potential change of control of the broker-dealer subsidiary of NHLD as substantially complete, for all of the issued and outstanding shares of NHLD’s common stock, par value $ 0.02 3.25 If more than 80% of the NHLD shares are tendered in the offer, NHLD will undergo a merger and will no longer be a public company. Following the closing of the tender offer, if less than 80 Following the closing of the tender offer, regardless of the number of shares purchased, Fortress will have the right to appoint a majority of the board of NHLD. If the Merger Agreement is terminated under certain circumstances as indicated in the Merger Agreement NHLD would be responsible for a termination fee of approximately $ 1.8 4.4 0.8 Amendment to At Market Issuance Sales Agreement On April 28, 2016, the Company entered into an amendment to its existing At Market Issuance Sales Agreement, or Sales Agreement, with MLV & Co. LLC, or MLV, pursuant to which it extended the termination date of the Sales Agreement to August 19, 2016. This amendment did not change any other material terms of the Sales Agreement.

Summary of Significant Accoun20

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period. The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the unaudited condensed consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding fiscal year. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Form 10-K, which was filed with the United States Securities and Exchange Commission (“SEC”) on March 15, 2016, from which the Company derived the balance sheet data at December 31, 2015. The Company’s unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries: Innmune Limited, Coronado SO, Cyprium Therapeutics, Inc., Escala, JMC, CB Securities Corporation, Avenue, Checkpoint, Mustang and Helocyte. All intercompany balances and transactions have been eliminated. The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period.
Use of Estimates	Use of Estimates The Company’s unaudited condensed consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, fair value measurements, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.
Reclassification	Reclassification Certain reclassifications have been made to prior year amounts to conform to the current year presentation in the condensed consolidated statements of cash flows.
Fair Value Measurement	Fair Value Measurement The Company follows accounting guidance on fair value measurements for financial assets and liabilities measured at fair value on a recurring basis. Under the accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance requires fair value measurements be classified and disclosed in one of the following three categories: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2: Observable inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. Certain of the Company’s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as accounts payable, accrued expenses and other current liabilities. The carrying value of the amount owed to Ovamed GmbH (“Ovamed”) upon the acquisition of certain manufacturing rights in December 2012 to under the amendment to our sublicense agreement with Ovamed has been recorded at its net present value, which approximates its fair value. The amounts due to Ovamed are included in current liabilities at March 31, 2016 and at December 31, 2015 on the condensed Consolidated Balance Sheets (see Note 9).
Segment Reporting	Segment Reporting The Company operates in one operating segment and, accordingly, no segment disclosures have been presented herein. All of the Company’s equipment, leasehold improvements and other fixed assets are physically located within the United States, and all agreements with the Company’s vendors are denominated in U.S. dollars.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at March 31, 2016 and at December 31, 2015 consisted of cash, money market funds and certificates of deposit in institutions in the United States. Balances at certain institutions have exceeded Federal Deposit Insurance Corporation insured limits and U.S. government agency securities.
Property and Equipment	Property and Equipment Office equipment is recorded at cost and depreciated using the straight-line method over the estimated useful life of each asset. Leasehold improvements are amortized over the shorter of the estimated useful lives or the term of the respective leases.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value, determined based on discounted cash flows.
Restricted Cash	Restricted Cash The Company records cash held in trust or pledged to secure certain debt obligations as restricted cash. As of March 31, 2016, the Company has $ 14.6 14.0 0.6
Investments at Fair Value	Investments at Fair Value The Company elects the fair value option for its long-term investments at fair value (see Note 4). The decision to elect the fair value option, which is irrevocable once elected, is determined on an instrument by instrument basis and applied to an entire instrument. The net gains or losses, if any, on an investment for which the fair value option has been elected are recognized as a change in fair value of investments on the condensed Consolidated Statements of Operations. The Company has various processes and controls in place to ensure that fair value is reasonably estimated. While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.
Intangible Asset Licenses	Intangible Asset Licenses The Company records the costs of acquired product distribution license rights as intangible asset-licenses in the condensed Consolidated Balance Sheets. Upon commencement of product sales, license rights will be amortized over the expected life of the product into product expense in the condensed Consolidated Statements of Operations. As of March 31, 2016, product sales related to the Company’s intangible asset licenses had not yet commenced (see Note 7).
Deferred Financing Costs	Deferred Financing Costs Financing costs incurred in connection with the promissory note for $ 15.0
Revenue Recognition	Reimbursement Arrangements and Collaborative Arrangements Checkpoint is reimbursed by TG Therapeutics, Inc. (“TGTX”), a related party, for its share of the cost of the license and product research and development costs under the collaboration agreement with them. The gross amount of these reimbursed costs are reported as revenue in the condensed Consolidated Statements of Operations, since the Company acts as a principal, bears credit risk and may perform part of the services required in the transactions. Consistent with Accounting Standards Codification (“ASC”) 605-45, Revenue Recognition - Principal Agent Considerations The Company recognizes revenue for the performance of services or the shipment of products when each of the following four criteria is met: (i) persuasive evidence of an arrangement exists; (ii) products are delivered or as services are rendered; (iii) the sales price is fixed or determinable; and (iv) collectability is reasonably assured. The Company follows ASC 605-25, Revenue Recognition - Multiple-Element Arrangements Collaborative Arrangements ASC 605-25 provides guidance relating to the separability of deliverables included in an arrangement into different units of accounting and the allocation of arrangement consideration to the units of accounting. The evaluation of multiple-element arrangements requires management to make judgments about (i) the identification of deliverables, (ii) whether such deliverables are separable from the other aspects of the contractual relationship, (iii) the estimated selling price of each deliverable, and (iv) the expected period of performance for each deliverable. To determine the units of accounting under a multiple-element arrangement, management evaluates certain separation criteria, including whether the deliverables have stand-alone value, based on the relevant facts and circumstances for each arrangement. Management then estimates the selling price for each unit of accounting and allocates the arrangement consideration to each unit utilizing the relative selling price method. The allocated consideration for each unit of accounting is recognized over the related obligation period in accordance with the applicable revenue recognition criteria. If there are deliverables in an arrangement that are not separable from other aspects of the contractual relationship, they are treated as a combined unit of accounting, with the allocated revenue for the combined unit recognized in a manner consistent with the revenue recognition applicable to the final deliverable in the combined unit. Payments received prior to satisfying the relevant revenue recognition criteria are recorded as deferred revenue in the condensed Consolidated Balance Sheets and recognized as revenue in the condensed Consolidated Statements of Operations when the related revenue recognition criteria are met. JMC’s co-promotion revenue for Dermasorb HC™ is based upon prescription volume over an established baseline
Research and Development	Research and Development Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on the Company’s behalf will be expensed as services are rendered or when the milestone is achieved. Research and development costs primarily consist of personnel related expenses, including salaries, benefits, travel, and other related expenses, stock-based compensation, payments made to third parties for license and milestone costs related to in-licensed products and technology, payments made to third party contract research organizations for preclinical and clinical studies, investigative sites for clinical trials, consultants, the cost of acquiring and manufacturing clinical trial materials, costs associated with regulatory filings, laboratory costs and other supplies. In accordance with ASC 730-10-25-1, Research and Development
Valuation of Warrants Related to NSC Note	In accordance with ASC 815 – Derivatives and Hedging , the Company classified the fair value of the warrants (“Contingently Issuable Warrants”) granted in connection with the NSC Note transferred to Avenue effective February 2015 as a derivative liability. The Company valued these Contingently Issuable Warrants using an option pricing model, and used estimates for an expected dividend yield, a risk-free interest rate, and expected volatility together with management’s estimate of the probability of issuance of the Contingently Issuable Warrants (see Note 4 and Note 8). At each reporting period, as long as the Contingently Issuable Warrants were potentially issuable and there was a potential for an insufficient number of authorized shares available to settle the Contingently Issuable Warrants, these Contingently Issuable Warrants will be revalued and any difference from the previous valuation date would be recognized as a change in fair value of subsidiary’s warrant liabilities in the condensed Consolidated Statements of Operations
Contingencies	Contingencies The Company records accruals for contingencies and legal proceedings expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated. If a loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed.
Stock-Based Compensation	Stock-Based Compensation The Company expenses stock-based compensation to employees over the requisite service period based on the estimated grant-date fair value of the awards and forfeiture rates. For stock-based compensation awards to non-employees, the Company remeasures the fair value of the non-employee awards at each reporting period prior to vesting and finally at the vesting date of the award. Changes in the estimated fair value of these non-employee awards are recognized as compensation expense in the period of change. The Company estimates the fair value of stock options grants using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment.
Income Taxes	Income Taxes The Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax effects attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company establishes a valuation allowance if it is more likely than not that the deferred tax assets will not be recovered based on an evaluation of objective verifiable evidence. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the largest amount of the benefit that is greater than 50
Non-Controlling Interests	Non-Controlling Interests Non-controlling interests in consolidated entities represent the component of equity in consolidated entities held by third parties. Any change in ownership of a subsidiary while the controlling financial interest is retained is accounted for as an equity transaction between the controlling and non-controlling interests (see Note 10).
Comprehensive Loss	Comprehensive Loss The Company’s comprehensive loss is equal to its net loss for all periods presented.
Recently Issued Accounting Standards	Recent Accounting Pronouncements In January 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Liabilities In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). ASU No. 2016-02 requires an entity to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. ASU No. 2016-02 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption is permitted. The Company currently in the process of evaluating the impact of adoption of ASU No. 2016-02 on the condensed consolidated financial statements and related disclosures. In March 2016, the FASB issued ASU No. 2016-08, “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations”. The purpose of ASU No. 2016-08 is to clarify the implementation of guidance on principal versus agent considerations. The amendments in ASU No. 2016-08 are effective for interim and annual reporting periods beginning after December 15, 2017. The Company is currently assessing the impact of ASU No. 2016-08 on the condensed consolidated financial statements and related disclosures. In March 2016, the FASB issued ASU No. 2016-09, “Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting”. The amendment is to simplify several aspects of the accounting for share-based payment transactions including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The amendments in ASU No. 2016-09 are effective for interim and annual reporting periods beginning after December 15, 2016. The Company is currently assessing the impact of ASU No. 2016-09 on the condensed consolidated financial statements and related disclosures.

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2016
Property Plant And Equipment [Abstract]
Components of Property and Equipment	Property and equipment consisted of the following: March 31, December 31, ($ in thousands) Useful Life (Years) 2016 2015 Computer equipment 3 $ 391 $ 13 Furniture and fixtures 5 338 69 Leasehold improvements 5 20 21 Construction in progress (1) N/A 1,909 274 Total property and equipment 2,658 377 Less: Accumulated depreciation (60) (68) Property and equipment, net $ 2,598 $ 309 (1) For build-out of the Company's new office in New York, NY.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2016
Schedule of Derivative Liabilities at Fair Value	Fair Value of Derivative Warrant ($ in thousands) Liability Beginning balance at January 1, 2016 $ 114 Fair value adjustment of derivative warrant liability 89 Ending balance at March 31, 2016 $ 203
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following tables classify into the fair value hierarchy financial instruments measured at fair value on a recurring basis on the condensed Consolidated Balance Sheets as of March 31, 2016 and December 31, 2015: Fair Value Measurement as of March 31, 2016 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Long-term investments, at fair value $ - $ - $ 1,567 $ 1,567 Liabilities Derivative warrant liability $ - $ - $ 203 $ 203 Fair Value Measurement as of December 31, 2015 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Long-term investments, at fair value $ - $ - $ 2,485 $ 2,485 Liabilities Derivative warrant liability $ - $ - $ 114 $ 114
Schedule of changes in fair value of financial instruments	Fair Value of Investment Long-term ($ in thousands) Other CB Pharma Total Balance at December 31, 2015 $ 250 $ 2,235 $ 2,485 Change in fair value of investments - (918) (918) Balance at March 31, 2016 $ 250 $ 1,317 $ 1,567 Fair Value of Investment Long-term ($ in thousands) Other CB Pharma Total Balance at December 31, 2014 $ 250 $ 3,910 $ 4,160 Change in fair value of investments - (215) (215) Balance at March 31, 2015 $ 250 $ 3,695 $ 3,945
Avenue [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	The fair value of the Avenue’s Contingently Issuable Warrants was determined by applying management’s estimate of the probability of issuance of the Contingently Issuable Warrants together with an option pricing model, with the following key assumptions: March 31, 2016 Risk-free interest rate 1.78 % Expected dividend yield - % Expected term in years 9.59 Expected volatility 83.00 % Probability of issuance of the warrant 45.00 %

Licenses Acquired (Tables)

Licenses Acquired (Tables)	3 Months Ended
	Mar. 31, 2016
Research and Development [Abstract]
Research and Development Arrangement, Contract to Perform for Others	For the three months ended March 31, 2016 and 2015, the Company’s research and development-licenses acquired are comprised of the following: For the Three Months Ended March 31, ($ in thousands) 2016 2015 Fortress Companies: Avenue $ - $ 2,000 Checkpoint - 2,000 Coronado SO - 1,179 Helocyte 83 - Mustang - 2,260 Total $ 83 $ 7,439

Debt and Interest (Tables)

Debt and Interest (Tables)	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Schedule Of Interest Expenses	Long-term debt to Israel Discount Bank (“IDB”) and National Securities Corporation (“NSC”) consists of the following as of March 31, 2016 and December 31, 2015: Interest ($ in thousands) March 31, 2016 December 31, Rate Maturity IDB Note $ 14,009 $ 14,009 2.25 % Feb - 2017 NSC Note 7,208 10,000 8.00 % Mar - 2018 Total notes payable, long-term 21,217 24,009 Less: Discount on notes payable 466 835 Total notes payable, long-term, net $ 20,751 $ 23,174
Schedule Of Interest Expenses For Debt Arrangements	The following table shows the details of interest expense for all debt arrangements during the periods presented. Interest expense includes contractual interest and amortization of the debt discount and amortization of fees associated with loan transaction costs, amortized over the life of the loan: For the Three Months Ended March 31, ($ in thousands) 2016 2015 IDB Note Interest $ 80 $ 69 Amortization of fees 1 1 Total IDB Note 81 70 NSC Debt Interest 167 72 Amortization of fees 368 20 Total NSC Debt 535 92 Ovamed Interest - 167 Total Ovamed - 167 LOC Fees Interest 4 2 Total LOC 4 2 Total Interest Expense $ 620 $ 331

Accrued Expenses and Other Lo25

Accrued Expenses and Other Long-Term Liabilities (Tables)	3 Months Ended
	Mar. 31, 2016
Payables and Accruals [Abstract]
Components of Accrued Expenses and Other Long-Term Liabilities	Accrued expenses and other long-term liabilities consisted of the following: March 31, December 31, ($ in thousands) 2016 2015 Accrued expenses: Professional fees $ 749 $ 382 Salaries, bonuses and related benefits 762 2,492 Ovamed manufacturing rights - short term component 1,500 1,500 Research and development 746 810 Dr. Falk Pharma milestone 2,828 2,717 COH upfront fee for sponsored research for PepVax (see Note 6) 1,007 - Accrued lease costs for abandoned properties 146 146 Other 521 523 Total accrued expenses $ 8,259 $ 8,570 Other long-term liabilities: Long-term accrued lease costs for abandoned properties 17 91 Deferred rent 2,399 493 Total other long-term liabilities $ 2,416 $ 584

Non-Controlling Interests (Tabl

Non-Controlling Interests (Tables)	3 Months Ended
	Mar. 31, 2016
Noncontrolling Interest [Abstract]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net	Non-controlling interests in consolidated entities are as follows: As of March 31, 2016 ($ in thousands) Avenue Coronado SO Mustang Checkpoint JMC Helocyte Total NCI equity share $ (560) $ (217) $ (359) $ 32,623 $ (299) $ (406) $ 30,782 Net loss attributed to non-controlling interests (108) (5) (70) (4,037) (121) (97) (4,438) Non-controlling interests in consolidated entities $ (668) $ (222) $ (429) $ 28,586 $ (420) $ (503) $ 26,344 As of December 31, 2015 ($ in thousands) Avenue Coronado SO Mustang Checkpoint JMC Total NCI equity share $ 6 $ 23 $ 14 $ 32,760 $ 79 $ 32,882 Net loss attributed to non-controlling interests (567) (240) (373) (3,855) (420) (5,455) Non-controlling interests in consolidated entities $ (561) $ (217) $ (359) $ 28,905 $ (341) $ 27,427
Components Of Non-Controlling Interests In Loss Of Consolidated Entities	The components of non-controlling interests in loss of consolidated entities are as follows: For the three months ended March 31, 2016 ($ in thousands) Avenue Coronado SO Mustang Checkpoint JMC Helocyte Total Non-controlling interests in loss of consolidated entities $ (108) $ (5) $ (70) $ (4,037) $ (121) $ (97) $ (4,438) Non-controlling ownership 11.5 % 13.0 % 10.0 % 62.7 % (1) 8.1 % 8.3 % (1) Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights. For the three months ended March 31, 2015 ($ in thousands) Coronado SO Mustang Checkpoint Total Non-controlling interests in loss of consolidated entities $ (160) $ (226) $ (93) $ (479) Non-controlling ownership 13.0 % 10.0 % 15.0 %

Net Loss per Common Share (Tabl

Net Loss per Common Share (Tables)	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Computations of Diluted Weighted Average Shares Outstanding	The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding, as the effect of including such securities would be anti-dilutive at the end of the periods March 31, 2016 and 2015: For the Three Months Ended March 31, 2016 2015 Warrants to purchase Common Stock 544,835 685,061 Options to purchase Common Stock 1,779,365 2,064,365 Unvested Restricted Stock 7,922,021 7,704,269 Unvested Restricted Stock Units 885,083 36,000 Total 11,131,304 10,489,695

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Share-based Compensation, Activity	The following table summarizes the stock-based compensation expense from stock option awards, restricted common stock awards, employee stock purchase programs and warrants granted by Fortress for the three months ended March 31, 2016 and 2015: For the Three Months Ended March 31, ($ in thousands) 2016 2015 Employee awards $ 1,584 $ 1,463 Non-employee awards 3 7 Fortress Companies (1) 1,279 - Total stock-based compensation expense $ 2,866 $ 1,470 (1) Consists of approximately $ 9,000 1.1 181,000
Schedule of Share-based Compensation, Stock Options, Activity	The following table summarizes Fortress stock option activities excluding activity related to Fortress Companies: Weighted average Total weighted remaining Weighted average average intrinsic contractual life Number of shares exercise price value (years) Options vested and expected to vest at December 31, 2015 1,779,365 $ 4.37 $ 666,396 6.32 Options granted - - - Options vested and expected to vest at March 31, 2016 1,779,365 $ 4.37 $ 853,984 6.07 Options vested and exercisable 1,082,168 $ 3.75 $ 805,651 5.62
Nonvested Restricted Stock Shares Activity	The following table summarizes Fortress’ restricted stock and restricted stock unit award activity, excluding activity related to Fortress Companies (which is discussed below): Weighted average Number of shares grant price Unvested balance at December 31, 2015 8,757,935 $ 2.47 Restricted stock granted 1,240,868 2.77 Restricted stock vested (989,782) 2.73 Restricted stock units granted 165,000 3.22 Restricted stock units cancelled (25,000) 3.71 Restricted stock units vested (341,917) 3.55 Unvested balance at March 31, 2016 8,807,104 $ 2.45
Schedule of Warrant Activities	Total weighted Weighted average Weighted average average intrinsic remaining contractual Number of shares exercise price value life (years) Outstanding as of December 31, 2015 569,835 $ 6.31 $ 120,700 1.84 Exercised (*) (25,000) 1.37 43,250 Outstanding as of March 31, 2016 544,835 $ 6.53 $ 103,800 1.67 Exercisable as of March 31, 2016 544,835 $ 6.53 $ 103,800 1.67 (*) - cashless
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	For the three months ended March 31, 2016 Risk-free interest rate 1.46% - 1.82 % Expected dividend yield - Expected term in years 5.23-6.95 Expected volatility 96.89% - 102.05 %

Summary of Significant Accoun29

Summary of Significant Accounting Policies - Additional Information (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2016USD ($)
Accounting Policies [Line Items]
Percentage of tax benefit likely of being realized	50.00%
Restricted Cash and Cash Equivalents	$ 14.6
Notes Payable	14
Hercules Note Payble [Member]
Accounting Policies [Line Items]
Restricted Cash and Cash Equivalents	0.6
Hercules Note Payble [Member] | Third Party [Member]
Accounting Policies [Line Items]
Deferred financing costs	$ 15

Property and Equipment - Compon

Property and Equipment - Components of Property and Equipment (Detail) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Total property and equipment		$ 2,658	$ 377
Less: Accumulated depreciation		(60)	(68)
Property and equipment, net		2,598	309
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment		$ 391	13
Useful Life (Years)		3 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment		$ 338	69
Useful Life (Years)		5 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment		$ 20	21
Useful Life (Years)		5 years
Construction in progress [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	[1]	$ 1,909	$ 274
[1]	For build-out of the Company's new office in New York, NY.

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended
	Jan. 31, 2016	Mar. 31, 2016	Mar. 31, 2015
Property Plant And Equipment [Line Items]
Depreciation		$ 4,000	$ 6,000
Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Impairment of Long-Lived Assets Held-for-use	$ 12,000

Fair Value Measurements - Avenu

Fair Value Measurements - Avenue's Contingently Issuable Warrants with option pricing model (Detail) - Warrant [Member] - Avenue [Member]	3 Months Ended
	Mar. 31, 2016
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	1.78%
Expected dividend yield	0.00%
Expected term in years	9 years 7 months 2 days
Expected volatility	83.00%
Probability of issuance of the warrant	45.00%

Fair Value Measurements - Fair

Fair Value Measurements - Fair value of derivative warrant liability (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Fair value adjustment of derivative warrant liability	$ 89	$ 0
Warrant [Member]
Beginning balance at January 1, 2016	114
Fair value adjustment of derivative warrant liability	89
Ending balance at March 31, 2016	$ 203

Fair Value Measurements - Finan

Fair Value Measurements - Financial Instruments Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term investments, at fair value	$ 1,567	$ 2,485
Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative warrant liability	203	114
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term investments, at fair value	0	0
Fair Value, Inputs, Level 1 [Member] | Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative warrant liability	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term investments, at fair value	0	0
Fair Value, Inputs, Level 2 [Member] | Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative warrant liability	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term investments, at fair value	1,567	2,485
Fair Value, Inputs, Level 3 [Member] | Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative warrant liability	$ 203	$ 114

Fair Value Measurements - Chang

Fair Value Measurements - Changes in Fair Value of Financial Instruments (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	$ 2,485	$ 4,160
Change in fair value of investments	(918)	(215)
Balance	1,567	3,945
CB Pharma Acquisitions Corp [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	2,235	3,910
Change in fair value of investments	(918)	(215)
Balance	1,317	3,695
Other Long-term Investments [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	250	250
Change in fair value of investments	0	0
Balance	$ 250	$ 250

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($)	1 Months Ended		3 Months Ended
	Oct. 31, 2015	Mar. 17, 2014	Mar. 31, 2016	Mar. 31, 2015	Feb. 29, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Method Investments		$ 250,000	$ 250,000			$ 250,000
Equity Method Investment, Ownership Percentage		35.00%
Share Price			$ 9.61
Fair Value Assumptions, Weighted Average Volatility Rate			25.60%
Investments in and Advances to Affiliates, at Fair Value, Period Increase (Decrease), Total			$ 900,000
Investment Owned, at Fair Value			$ 1,300,000
Percentage of Outstanding Stock To Be Issued Upon Exercise of Warrants			25.00%
Fair Value Adjustment of Warrants			$ 89,000	$ 0
Business Acquisition, Percentage of Voting Interests Acquired			10.25%
CB Pharma Acquisitions Corp [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Working Capital			$ 500,000
Working Capital Committed			$ 300,000
Common Stock Subject to Mandatory Redemption [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Net Assets					$ 42,500,000
Non Redeemable warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Share Price			$ 0.10
Redeemable warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Share Price			$ 0.10
NSE Note [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant Expiration Period			10 years
Fair Value Adjustment of Warrants	$ 3,000,000
Binomial Lattice Model [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Exercise Price			$ 11.50
Fair Value Assumptions, Risk Free Interest Rate			1.21%
Fair Value Assumptions, Expected Volatility Rate			25.60%
Binomial Lattice Model [Member] | Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Share Price			$ 0.98
Ghaidarov Model [Member] | Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Share Price			0.94
Private Units [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Share Price			1
Share Price			9.82
Insider Shares [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Share Price			$ 0.97
Argus Neurooptics Llc [Member] | Class A Preferred Stock [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Shares Received Under Purchase Agreement		$ 13,409,962
Percentage Of Shares Received Under Purchase Agreement		83.00%
Preferred Units, Issued		16,091,954

Licenses Acquired - Summary Of

Licenses Acquired - Summary Of Research and Development Arrangement Contract (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total	$ 83	$ 7,439
Mustang Therapeutics, Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total	0	2,260
Checkpoint Therapeutics, Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total	0	2,000
Coronado SO Co, Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total	0	1,179
Helocyte [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total	83	0
Avenue Therapeutics, Inc. [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total	$ 0	$ 2,000

Licenses Acquired - Additional

Licenses Acquired - Additional Information (Detail) - USD ($)

Jan. 11, 2016

May. 11, 2015

Apr. 02, 2015

Feb. 29, 2016

Oct. 31, 2015

Sep. 30, 2015

Jul. 16, 2015

Jun. 17, 2015

May. 31, 2015

Apr. 28, 2015

Mar. 17, 2015

Feb. 28, 2015

Mar. 31, 2016

Mar. 31, 2015

Dec. 31, 2015

Feb. 17, 2015

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payments to Acquire Intangible Assets

$ 200,000

$ 1,250,000

Research And Development In Process

83,000

7,439,000

Stock Issued During Period, Value, Issued for Services

2,000

1,000

Research And Development Expense

$ 7,736,000

1,642,000

Share Price

$ 9.61

Reimbursment Of Cost Recognised As Revenue

$ 300,000

$ 300,000

NeuPharma [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Research And Development In Process

$ 1,000,000

City Of Hope [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Marketability Percentage Of Invested Capital

44.80%

Payments for Fees

$ 2,000,000

Stock Issued During Period, Shares, Other

1,000,000

Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent

30.00%

Share Price

$ 0.147

Stock Issued During Period, Value, Other

$ 100,000

National Institutes of Health [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payment of Upfront Milestone Fees

$ 700,000

New Zealand Pharmaceuticals Ltd [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Reimbursement Revenue

600,000

Dana-Farber [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Shares Issued, Price Per Share

$ 0.065

$ 4.39

Stock Issued During Period, Shares, Issued for Services

500,000

136,803

Stock Issued During Period, Value, Issued for Services

$ 32,500

$ 600,000

Escala Therapeutics, Inc [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payment of Upfront Fees

$ 1,300,000

Collaboration Agreement with TGTX [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payments for Fees

17,000,000,000

500,000

500,000

Collaboration Agreement with TGTX [Member] | NeuPharma [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payments for Fees

25,000

Collaboration Agreement with TGTX [Member] | TG Therapeutics, Inc [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payments for Fees

17,000

500,000

Coronado SO Co, Inc [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Research And Development In Process

$ 0

$ 1,179,000

Payments for Fees

$ 900,000

Stock Issued During Period, Shares, Other

150,000

Research And Development Expense

$ 500,000

Licensing Agreements [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payments to Acquire Intangible Assets

$ 150,000

$ 35,000

$ 50,000

Intangible Assets, Net (Excluding Goodwill), Total

$ 500,000

Licensing Agreements [Member] | City Of Hope [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Marketability Percentage Of Invested Capital

44.50%

Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent

30.00%

Share Price

$ 0.097

Stock Issued During Period, Value, Other

$ 48,500

Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Shares Issued

500,000

Licensing Agreements [Member] | Dana-Farber [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payments for Fees

$ 1,000,000

Licensing Agreements [Member] | Coronado SO [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Marketability Percentage Of Invested Capital

44.80%

Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent

30.00%

Share Price

$ 1.19

Licensing Agreements [Member] | IV Tramadol [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payments to Acquire Intangible Assets

$ 1,000,000

Payments for Fees

$ 2,000,000

Avenue Therapeutics, Inc. [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Shares Issued, Price Per Share

$ 0.146

Research And Development Expense

$ 5,000

Debt Instrument, Fee Amount

$ 3,000,000

Milestones and Sponsored Rese39

Milestones and Sponsored Research Agreements - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended
	Mar. 31, 2016	Feb. 29, 2016	Mar. 31, 2016	Mar. 31, 2015
Milestones and Sponsored Research Agreements [Line Items]
Research And Development Expense			$ 7,736	$ 1,642
Terms Of Clinical Reasearch Support Agreement		Under the terms of the agreement an additional $1.0 million is due when certain clinical milestones are achieved using the initial $1.0 million. An additional $2.4 million is due upon the achievement of certain clinical and other milestones. The agreement expires upon the delivery of a final study report or May 31, 2018 unless terminated earlier.
Mustang Bio, Inc [Member]
Milestones and Sponsored Research Agreements [Line Items]
Research and Development Arrangement, Contract to Perform for Others, Compensation Earned			2,000
Research And Development Expense			500
UCLB [Member]
Milestones and Sponsored Research Agreements [Line Items]
Research and Development Expense Payable, Milestone Payment	$ 22,000		22,000
Milestone Payments			400
Payment of Upfront Fees			$ 100
UCLB [Member] | Maximum [Member]
Milestones and Sponsored Research Agreements [Line Items]
Royalty Percentage			5.00%
UCLB [Member] | Minimum [Member]
Milestones and Sponsored Research Agreements [Line Items]
Royalty Percentage			3.00%
City Of Hope [Member]
Milestones and Sponsored Research Agreements [Line Items]
Payments to Acquire in Process Research and Development	1,000	$ 1,000
Research and Development Expense Payable, Milestone Payment	$ 2,000	$ 3,400	$ 2,000

Intangible Asset Licenses - Add

Intangible Asset Licenses - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Jan. 31, 2016	Mar. 31, 2016	Mar. 31, 2015
Indefinite-lived Intangible Assets [Line Items]
Payments to Acquire Intangible Assets		$ 200	$ 1,250
Journey Medical Corporation [Member]
Indefinite-lived Intangible Assets [Line Items]
License Costs			700
Payments to Acquire Intangible Assets	$ 200		$ 1,300

Debt and Interest - Long-term d

Debt and Interest - Long-term debt (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Debt [Line Items]
Total notes payable, long-term	$ 21,217		$ 24,009
Less: Discount on notes payable	446		835
Total notes payable, long-term, net	20,751		23,174
IDB Note [Member]
Debt [Line Items]
Total notes payable, long-term	$ 14,009		14,009
Interest Rate	2.25%
Maturity Date	Feb - 2017
NSC Note [Member]
Debt [Line Items]
Total notes payable, long-term	$ 7,208		$ 10,000
Interest Rate	8.00%
Maturity Date	Mar - 2018	36 months

Debt and Interest - Schedule of

Debt and Interest - Schedule of Interest Expenses for Debt Arrangements (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Debt [Line Items]
Interest expense related to the Hercules loan	$ 620	$ 331
LOC Fees [Member]
Debt [Line Items]
Interest	4	2
Interest and Debt Expense, Total	4	2
IDB Note [Member]
Debt [Line Items]
Interest	80	69
Amortization of fees	1	1
Interest and Debt Expense, Total	81	70
NSC Debt [Member]
Debt [Line Items]
Interest	167	72
Amortization of fees	368	20
Interest and Debt Expense, Total	535	92
Ovamed [Member]
Debt [Line Items]
Interest	0	167
Interest and Debt Expense, Total	$ 0	$ 167

Debt and Interest- Additional I

Debt and Interest- Additional Information (Detail) - USD ($)	1 Months Ended		3 Months Ended
	Feb. 29, 2016	Feb. 13, 2014	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Mar. 17, 2014
Debt [Line Items]
Notes Payable			$ 14,000,000
Sale of Stock, Percentage of Ownership after Transaction			25.00%
Repayments of Debt	$ 2,800,000
Amortization of Debt Discount (Premium)	324,000		$ 369,000	$ 0
Equity Method Investment, Ownership Percentage						35.00%
Letter of Credit [Member]
Debt [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			2.00%
Letters of Credit Outstanding, Amount			$ 1,700,000
Israel Discount Bank Of New York [Member]
Debt [Line Items]
Debt Instrument, Face Amount		$ 15,000,000
Notes Payable			$ 14,000,000
IDB Promissory Note Payable [Member]
Debt [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			2.25%
Debt Instrument, Face Amount		15,000,000
IDB Promissory Note Payable [Member] | Minimum [Member]
Debt [Line Items]
Debt Instrument, Unused Borrowing Capacity, Amount		100,000
NSC Note [Member]
Debt [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			8.00%
Debt Instrument, Fee Amount					$ 900,000
Notes Payable				$ 10,000,000
Debt Instrument, Maturity Date, Description			Mar - 2018	36 months
Debt Instrument, Interest Rate, Effective Percentage					12.40%
NSC Note [Member] | Warrant [Member]
Debt [Line Items]
Debt Instrument, Unamortized Discount (Premium), Net, Total			$ 113,500
Long-term Debt, Fair Value	174,000
Hercules Note Payble [Member]
Debt [Line Items]
Debt Instrument, Periodic Payment, Interest		100,000
Debt Instrument, Periodic Payment		$ 14,000,000
National Holding’s Corporation Inc [Member] | Board of Directors Chairman [Member]
Debt [Line Items]
Equity Method Investment, Ownership Percentage			4.20%
NSC [Member]
Debt [Line Items]
Debt Instrument, Term			10 years
Checkpoint [Member]
Debt [Line Items]
Debt Instrument, Unamortized Discount (Premium), Net, Total	$ 324,000
Checkpoint [Member] | NSC Note [Member]
Debt [Line Items]
Fees related to the loan agreement			$ 2,800,000
Avenue [Member]
Debt [Line Items]
Debt Instrument, Unamortized Discount (Premium), Net, Total			267,500
Avenue [Member] | NSC Note [Member]
Debt [Line Items]
Fees related to the loan agreement			$ 3,000,000

Accrued Expenses and Other Lo44

Accrued Expenses and Other Long-Term Liabilities - Components of Accrued Expenses and Other Long-Term Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Accrued expenses:
Professional fees	$ 749	$ 382
Salaries, bonuses and related benefits	762	2,492
Ovamed manufacturing rights - short term component	1,500	1,500
Research and development	746	810
Dr. Falk Pharma milestone	2,828	2,717
COH upfront fee for sponsored research for PepVax (see Note 6)	1,007	0
Accrued lease costs for abandoned properties	146	146
Other	521	523
Total accrued expenses	8,259	8,570
Other long-term liabilities:
Long-term accrued lease costs for abandoned properties	17	91
Deferred rent	2,399	493
Total other long-term liabilities	$ 2,416	$ 584

Non-Controlling Interests - Sum

Non-Controlling Interests - Summary Of Non-controlling Interests in Consolidated Entities (Detail) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Noncontrolling Interest [Line Items]
NCI equity share	$ 30,782		$ 32,882
Net loss attributed to non-controlling interests	(4,438)	$ (479)	(5,455)
Non-controlling interests in consolidated entities	26,344		27,427
Avenue [Member]
Noncontrolling Interest [Line Items]
NCI equity share	(560)		6
Net loss attributed to non-controlling interests	(108)		(567)
Non-controlling interests in consolidated entities	(668)		(561)
Coronado SO Co, Inc [Member]
Noncontrolling Interest [Line Items]
NCI equity share	(217)		23
Net loss attributed to non-controlling interests	(5)	(160)	(240)
Non-controlling interests in consolidated entities	(222)		(217)
Mustang Therapeutics, Inc [Member]
Noncontrolling Interest [Line Items]
NCI equity share	(359)		14
Net loss attributed to non-controlling interests	(70)	(226)	(373)
Non-controlling interests in consolidated entities	(429)		(359)
Checkpoint Therapeutics, Inc [Member]
Noncontrolling Interest [Line Items]
NCI equity share	32,623		32,760
Net loss attributed to non-controlling interests	(4,037)	$ (93)	(3,855)
Non-controlling interests in consolidated entities	28,586		28,905
JMC [Member]
Noncontrolling Interest [Line Items]
NCI equity share	(299)		79
Net loss attributed to non-controlling interests	(121)		(420)
Non-controlling interests in consolidated entities	(420)		$ (341)
Helocyte [Member]
Noncontrolling Interest [Line Items]
NCI equity share	(406)
Net loss attributed to non-controlling interests	(97)
Non-controlling interests in consolidated entities	$ (503)

Non-Controlling Interests - S46

Non-Controlling Interests - Summary Of Components of Non-Controlling Interests in Loss of Consolidated Entities (Detail) - USD ($) $ in Thousands	3 Months Ended			12 Months Ended
	Mar. 31, 2016		Mar. 31, 2015	Dec. 31, 2015
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities	$ (4,438)		$ (479)	$ (5,455)
Avenue [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities	$ (108)			(567)
Non-controlling ownership	11.50%
Coronado SO Co, Inc [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities	$ (5)		$ (160)	(240)
Non-controlling ownership	13.00%		13.00%
Mustang Therapeutics, Inc [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities	$ (70)		$ (226)	(373)
Non-controlling ownership	10.00%		10.00%
Checkpoint Therapeutics, Inc [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities	$ (4,037)		$ (93)	(3,855)
Non-controlling ownership	62.70%	[1]	15.00%
JMC [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities	$ (121)			$ (420)
Non-controlling ownership	8.10%
Helocyte [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities	$ (97)
Non-controlling ownership	8.30%
[1]	Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights.

Net Loss per Common Share - Com

Net Loss per Common Share - Computations of Diluted Weighted Average Shares Outstanding (Detail) - shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	11,131,304	10,489,695
Warrants to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	544,835	685,061
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	1,779,365	2,064,365
Unvested Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	7,922,021	7,704,269
Unvested Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	885,083	36,000

Net Loss per Common Share - Add

Net Loss per Common Share - Additional Information (Detail) - shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount	11,131,304	10,489,695
Restricted Stock [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount	8,059,258

Stockholders' Equity - Employee

Stockholders' Equity - Employee Stock Purchase Programs (Detail) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		$ 2,866	$ 1,470
Fortress Companies [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	[1]	1,279	0
Employee Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		1,584	1,463
Non-Employee Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		$ 3	$ 7
[1]	Consists of approximately $9,000 of Avenue's compensation expenses, approximately $1.1 million of Checkpoint's compensation expense, and approximately $181,000 of JMC's compensation expenses on equity grants for the three months ended March 31, 2016.

Stockholders' Equity - Stock Op

Stockholders' Equity - Stock Option Activity (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares, Options vested and expected to vest	1,779,365
Number of shares, Options granted	0	1,500,000
Number of shares, Options vested and expected to vest	1,779,365		1,779,365
Number of shares, Options vested and exercisable	1,082,168
Weighted Average Exercise Price, Options vested and expected to vest	$ 4.37
Weighted Average Exercise Price, Options granted	0
Weighted Average Exercise Price, Options vested and expected to vest	4.37		$ 4.37
Weighted Average Exercise Price, Options vested and exercisable	$ 3.75
Total Weighted Average Intrinsic Value, Options vested and expected to vest	$ 666,396
Total Weighted Average Intrinsic Value, Options granted	0
Total Weighted Average Intrinsic Value, Options vested and expected to vest	853,984		$ 666,396
Total Weighted Average Intrinsic Value, Options vested and exercisable	$ 805,651
Weighted Average Remaining Contractual Life, Options vested and expected to vest	6 years 25 days		6 years 3 months 25 days
Weighted Average Remaining Contractual Life, Options vested and exercisable	5 years 7 months 13 days

Stockholders' Equity - Restrict

Stockholders' Equity - Restricted Stock Activity (Detail) - Restricted Stock [Member]	3 Months Ended
	Mar. 31, 2016$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares, Unvested balance | shares	8,757,935
Number of shares, Restricted stock granted | shares	1,240,868
Number of shares, Restricted stock vested | shares	(989,782)
Number of shares, Restricted stock units granted | shares	165,000
Number of shares, Restricted units cancelled | shares	(25,000)
Number of shares, Restricted stock units vested | shares	(341,917)
Number of shares, Unvested balance | shares	8,807,104
Weighted average grant price, Unvested balance | $ / shares	$ 2.47
Weighted average grant price, Restricted stock granted | $ / shares	2.77
Weighted average grant price, Restricted stock vested | $ / shares	2.73
Weighted average grant price, Restricted stock units granted | $ / shares	3.22
Weighted average grant price, Restricted stock units cancelled | $ / shares	3.71
Weighted average grant price, Restricted stock units vested | $ / shares	3.55
Weighted average grant price, Unvested balance | $ / shares	$ 2.45

Stockholders' Equity - summariz

Stockholders' Equity - summarizes Fortress warrant activities (Detail) - Warrant [Member] - USD ($)		3 Months Ended	12 Months Ended
		Mar. 31, 2016	Dec. 31, 2015
Subsidiary or Equity Method Investee [Line Items]
Number of shares, Outstanding		569,835
Number of shares, Exercised	[1]	(25,000)
Number of shares, Outstanding		544,835	569,835
Number of shares, Exercisable		544,835
Weighted average exercise price, Outstanding		$ 6.31
Weighted average exercise price, Exercised	[1]	1.37
Weighted average exercise price, Outstanding		6.53	$ 6.31
Weighted average exercise price, Exercisable		$ 6.53
Total weighted average instrinsic value, Outstanding		$ 120,700
Total weighted average intrinsic value, Exercised	[1]	43,250
Total weighted average instrinsic value, Outstanding		103,800	$ 120,700
Total weighted average intrinsic value, Exercisable		$ 103,800
Weighted average remaining contractual life (years), Outstanding		1 year 8 months 1 day	1 year 10 months 2 days
Weighted average remaining contractual life, Exercisable (years)		1 year 8 months 1 day
[1]	cashless

Stockholders' Equity - The fair

Stockholders' Equity - The fair value of options (Detail) - Journey Medical Corporation [Member]	3 Months Ended
	Mar. 31, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate, Minimum	1.46%
Risk-free interest rate, Maximum	1.82%
Expected dividend yield	0.00%
Expected volatility, Minimum	96.89%
Expected volatility, Maximum	102.05%
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term in years	5 years 2 months 23 days
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term in years	6 years 11 months 12 days

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)

Jul. 15, 2016

Jan. 08, 2016

Jul. 15, 2015

Mar. 30, 2016

Mar. 28, 2016

Feb. 29, 2016

Feb. 23, 2016

Jan. 31, 2016

Feb. 28, 2014

Mar. 31, 2016

Mar. 31, 2015

Dec. 31, 2015

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Stock-based compensation weighted-average vesting period

1 month 6 days

Employee Stock Purchase Plan to eligible employees, Reckoning fair value percentage during offering period

85.00%

Employee Stock Purchase Plan to eligible employees, compensation expense recognized

$ 0

$ 9,000

Share Price

$ 9.61

Research And Development Expense

$ 7,736,000

1,642,000

General And Administrative Expense

7,932,000

$ 3,490,000

Allocated Share-based Compensation Expense

$ 1,100,000

Fair Value Assumptions, Weighted Average Volatility Rate

25.60%

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross

0

1,500,000

Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options

$ 62,000

Share-based Compensation

$ 2,866,000

$ 1,470,000

Stock Issued During Period, Shares, New Issues

10,000

Long-Term Incentive Program [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Class of Warrant or Right, Outstanding

500,000

Weighted Market Value Percentage of Invested Capital

44.80%

Weighted Average Cost Percentage of Capital

30.00%

Capital Units, Authorized

100,000,000

Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Shares Granted

1.00%

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost, Total

$ 2,200,000

Checkpoint s 2015 Incentive Plan [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

83.00%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

1.50%

Share Price

$ 4.39

Checkpoint [Member] | Private Placement [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 7

Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total

$ 126,640

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

3,500

Warrant Purchase Price Per Unit

$ 45,000

Warrants Issued

44,324

Proceeds from Issuance of Private Placement

$ 600,000

Chief Executive Officer [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross

1,900,000

3,900,000

Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost

$ 400,000

Dr. Rosenwald [Member] | Long-Term Incentive Program [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period

510,434

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value

$ 2.37

Mr. Weiss [Member] | Long-Term Incentive Program [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period

510,434

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value

$ 2.4

Director [Member] | Checkpoint s 2015 Incentive Plan [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total

50,000

Employee [Member] | Checkpoint s 2015 Incentive Plan [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total

50,000

Avenue Therapeutics, Inc. [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Research And Development Expense

$ 5,000

Allocated Share-based Compensation Expense

$ 9,000

Weighted Market Value Percentage of Invested Capital

44.80%

Weighted Average Cost Percentage of Capital

30.00%

Shares Issued, Price Per Share

$ 0.146

Avenue Therapeutics, Inc. [Member] | Chief Executive Officer [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Stock Issued During Period, Shares, Issued for Services

1,000,000

Avenue Therapeutics, Inc. [Member] | Share-based Compensation Award, Tranche One [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage

50.00%

Avenue Therapeutics, Inc. [Member] | Share-based Compensation Award, Tranche Two [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage

12.50%

Avenue Therapeutics, Inc. [Member] | Share-based Compensation Award, Tranche Three [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage

50.00%

Journey Medical Corporation [Member] | Employee [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Weighted Market Value Percentage of Invested Capital

44.50%

Weighted Average Cost Percentage of Capital

30.00%

Shares Issued, Price Per Share

$ 0.65

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total

305,000

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

0.00%

Checkpoint Therapeutics, Inc [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

83.00%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

1.50%

Share Price

$ 4.39

$ 0.065

Allocated Share-based Compensation Expense

$ 800,000

Fair Value Assumptions, Weighted Average Volatility Rate

30.00%

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage

25.00%

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

48 months

Weighted Average Cost Percentage of Capital

44.80%

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value

$ 4.39

JMC [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Allocated Share-based Compensation Expense

$ 181,000

Helocyte Inc [Member] | Consultants [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

83.00%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

1.50%

Share Price

$ 0.097

Stock Issued During Period, Shares, Issued for Services

150,000

Helocyte Inc [Member] | Chief Executive Officer [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Share Price

$ 0.097

Stock Issued During Period, Shares, Issued for Services

1,000,000

Research and Development Expense [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Allocated Share-based Compensation Expense

1,300,000

$ 300,000

General and Administrative Expense [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Allocated Share-based Compensation Expense

1,600,000

$ 1,200,000

General and Administrative Expense [Member] | Checkpoint s 2015 Incentive Plan [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Share-based Compensation

300,000

General and Administrative Expense [Member] | Helocyte Inc [Member] | Consultants [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Share-based Compensation

62,000

General and Administrative Expense [Member] | Helocyte Inc [Member] | Chief Executive Officer [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Share-based Compensation

$ 500,000

Restricted Stock [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Stock-based compensation weighted-average vesting period

2 years 8 months 12 days

Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options

$ 4,100,000

Restricted Stock [Member] | General and Administrative Expense [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Share-based Compensation

$ 35,000

Restricted Stock Units (RSUs) [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Stock-based compensation weighted-average vesting period

1 year 3 months 18 days

Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options

$ 700,000

Employee Stock Option [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Common Stock issued in connection with the first ESPP offering

91,192

Common Stock, Capital Shares Reserved for Future Issuance

108,808

Employee Stock Option [Member] | General and Administrative Expense [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Share-based Compensation

$ 100,000

Related Party Note - Additional

Related Party Note - Additional Information (Detail) - USD ($)	Jan. 11, 2016	May. 31, 2015	Mar. 20, 2015	Mar. 17, 2015	Feb. 17, 2015	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Related Party Transaction [Line Items]
Interest own in percent by principal stockholder or director						15.40%		14.80%
Costs and Expenses, Related Party						$ 63,000	$ 40,000
Lessee Leasing Arrangements, Operating Leases, Term of Contract						5 years
Agreement Description Terms			(i) issue annually to the Company, on the anniversary date of the Founders Agreement, shares of common stock equal to to two and one half percent (2.5%) of the fully-diluted outstanding equity of Helocyte at the time of issuance; (ii) pay an equity fee in shares of Helocyte common stock, payable within five (5) business days of the closing of any equity or debt financing for Helocyte or any of its respective subsidiaries that occurs after the effective date of the Founders Agreement and ending on the date when Fortress no longer has majority voting control in Helocyte’s voting equity, equal to two and one half percent (2.5%) of the gross amount of any such equity or debt financing; and (iii) pay a cash fee equal to four and one half percent (4.5%) of our annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a change in control (as it is defined in the Founders Agreement), the Company will pay a one-time change in control fee equal to five (5x) times the product of (i) monthly net sales for the twelve (12) months immediately preceding the change in control and (ii) four and one-half percent (4.5%).	(i) issue annually to the Company, on the anniversary date of the Founders Agreement, shares of Checkpoint common stock equal to two and one half percent (2.5%) of the fully-diluted outstanding equity of Checkpoint at the time of issuance; (ii) pay an equity fee in shares of Checkpoint common stock, payable within five (5) business days of the closing of any equity or debt financing for Checkpoint or any of its respective subsidiaries that occurs after the effective date of the Founders Agreement and ending on the date when the Company no longer has majority voting control in Checkpoint’s voting equity, equal to two and one half percent (2.5%) of the gross amount of any such equity or debt financing; and (iii) pay a cash fee equal to four and one half percent (4.5%) of its annual net sales, payable on an annual basis, within 90 days of the end of each calendar year. In the event of a change in control (as defined in the Founders Agreement), the Company will pay a one-time change in control fee equal to five times (5x) the product of (i) monthly net sales for the 12 months immediately preceding the change in control and (ii) four and one half percent (4.5%)	(i) issue annually to the Company, on the anniversary date of the Founders Agreement, shares of common stock equal to to two and one half percent (2.5%) of the fully-diluted outstanding equity of Avenue at the time of issuance; (ii) pay an equity fee in shares of Avenue common stock, payable within five (5) business days of the closing of any equity or debt financing for Avenue or any of its respective subsidiaries that occurs after the effective date of the Founders Agreement and ending on the date when Fortress no longer has majority voting control in Avenue’s voting equity, equal to two and one half percent (2.5%) of the gross amount of any such equity or debt financing; and (iii) pay a cash fee equal to four and one half percent (4.5%) of our annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a change in control (as it is defined in the Founders Agreement), the Company will pay a one-time change in control fee equal to five (5x) times the product of (i) monthly net sales for the twelve (12) months immediately preceding the change in control and (ii) four and one-half percent (4.5%).
Prepaid Rent						$ 199,000
Lease Sharing Agreements, Contributions to Property Under Lease						2,300,000
Reimbursment Of Cost Recognised As Revenue	$ 300,000					$ 300,000
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Interest own in percent by principal stockholder or director						12.90%		12.20%
Chord Advisors, LLC [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party		$ 10,000
Cb Pharma Acquisition Corp [Member]
Related Party Transaction [Line Items]
Working Capital						$ 500,000
TG Therapeutics, Inc [Member]
Related Party Transaction [Line Items]
Accounts Receivable, Net, Total						100,000
Operating Leases, Rent Expense						1,100,000
Prepaid Rent						79,800
Due from Related Parties, Current						$ 1,000,000
Percentage of Rentable Area						40.00%
Lease Improvement Cost Assosciate With Lease						$ 5,100,000
TG Therapeutics, Inc [Member] | Cb Pharma Acquisition Corp [Member]
Related Party Transaction [Line Items]
Payments for Fees						300,000		$ 200,000
Checkpoint [Member] | Chord Advisors, LLC [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party		7,500
OPPM [Member]
Related Party Transaction [Line Items]
Operating Leases, Rent Expense						500,000
Prepaid Rent						39,800
Due from Related Parties, Current						$ 200,000
Percentage of Rentable Area						20.00%
Lease Improvement Cost Assosciate With Lease						$ 5,100,000
Collaboration Agreement with TGTX [Member]
Related Party Transaction [Line Items]
Payments for Fees						17,000,000,000	$ 500,000	500,000
Collaboration Agreement with TGTX [Member] | TG Therapeutics, Inc [Member]
Related Party Transaction [Line Items]
Payments for Fees						$ 17,000		$ 500,000
Management Services Agreement [Member]
Related Party Transaction [Line Items]
Annual Consulting Fee			$ 500,000	$ 500,000	$ 500,000
Increase in Annual Consulting Fee			1,000,000	1,000,000	1,000,000
Excess In Net Assets Value			$ 100,000,000	100,000,000	100,000,000
Management Services Agreement [Member] | Checkpoint [Member]
Related Party Transaction [Line Items]
Long-term Debt, Gross				$ 2,800,000
Management Services Agreement [Member] | Founders Agreement [Member]
Related Party Transaction [Line Items]
Debt Issuance Cost					$ 3,000,000
Avenue [Member] | Chord Advisors, LLC [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party		$ 5,000

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended
	Apr. 27, 2016	Mar. 31, 2016	Dec. 31, 2015
Subsequent Event [Line Items]
Common Stock Par Or Stated Value Per Share		$ 0.001	$ 0.001
Subsequent Event [Member]
Subsequent Event [Line Items]
Reimbursement Of Transaction Expenses	$ 0.8
Subsequent Event [Member] | Parent [Member]
Subsequent Event [Line Items]
Merger Agreement Termination Fee	$ 4.4
Subsequent Event [Member] | National Holdings Corporation [Member]
Subsequent Event [Line Items]
Merger Agreement, Minimum percentage of Shares in Tender Offer to Completed Merger	80.00%
Merger Agreement Termination Fee	$ 1.8
Common Stock Par Or Stated Value Per Share	$ 0.02
Business Acquisition, Share Price	$ 3.25